[ad_1]
The American Pfizer and the German BioNTech announced on November 18 the end of the clinical trials of their vaccine with a 95% effectiveness in the prevention of Covid-19.
The CEO of the German biotech company, Ugur Sahin, predicts that the first vaccines in Europe can be made before Christmas.
In the rest of the world, coats in the United States pending FDA approval will be administered a little later.
Three vaccines against Covid-19 with 90% or more effectiveness
Of the 11 projects in phase 3 of the clinical trials, the last one before the application for manufacturing and marketing authorization, there are three that presented efficiency rates equal to or greater than 90%: Pfizer / BioNTech, Moderna and the Russian Sputnik vaccine have encouraging results.
Still in phase 2 of clinical trials, but showing safety and efficacy in older people, the age group most vulnerable to Covid-19, the vaccine developed by the University of Oxford and the pharmaceutical company AstraZeneca – ChAdOx1 nCoV-19 -You must present the final results of the last phase “before Christmas,” says the leader of the investigation.
A Coronavac, the vaccine developed by Chinese laboratories Sinovac, is showing a high efficacy rate in the volunteers it was administered to, but is still in phase 2 clinical trials.
SEE MORE ON THE NEW SPECIAL CORONAVIRUS
The latest news at https://sicnoticias.pt/ultimas
